The PRIME Type 2 Diabetes Model: a novel, patient-level model for estimating long-term clinical and cost outcomes in patients with type 2 diabetes mellitus. (31st December 2022)

• Record Type: Journal Article
• Authors: Pollock, Richard F.; Norrbacka, Kirsi; Boye, Kristina S.; Osumili, Beatrice; Valentine, William J.
• Is Part Of: Journal of medical economics. Volume 25:Number 1(2022)
• Page Start: 393
• Page End: 402
• Publication Date: 2022-12-31
• Subjects: Cost-effectiveness -- model -- risk prediction -- type 2 diabetes mellitus; I10 -- I1 -- I -- C63 -- C6 -- C; Medical care -- Cost control -- Periodicals; Medical economics -- Periodicals; 362.10941
• DOI: 10.1080/13696998.2022.2035132
• Languages: English
• ISSNs: 1369-6998

Abstract

Abstract: Background and Aims: The growing burden of diabetes mellitus and recent progress in understanding cardiovascular outcomes for type 2 diabetes (T2D) patients continue to make the disease a priority for healthcare decision-makers around the world. Our objective was to develop a new, product-independent model capable of projecting long-term clinical and cost outcomes for populations with T2D to support health economic evaluation. Methods: Following a systematic literature review to identify longitudinal study data, existing T2D models and risk formulae for T2D populations, a model was developed (the PRIME Type 2 Diabetes Model [PRIME T2D Model]) in line with good practice guidelines to simulate disease progression, diabetes-related complications and mortality. The model runs as a patient-level simulation and is capable of simulating treatment algorithms and risk factor progression, and projecting the cumulative incidence of macrovascular and microvascular complications as well as hypoglycemic events. The PRIME T2D Model can report clinical outcomes, quality-adjusted life expectancy, direct and indirect costs, along with standard measures of cost-effectiveness and is capable of probabilistic sensitivity analysis. Several approaches novel to T2D modeling were utilized, such as combining risk formulae using a weighted model averaging approach that takes into account patient characteristics to evaluate complication risk. Results: Validation analyses comparing modeled outcomes with published studies demonstrated that the PRIME T2D Model projects long-term patient outcomes consistent with those reported for a number of long-term studies, including cardiovascular outcomes trials. All root mean squared deviation (RMSD) values for internal validations (against published studies used to develop the model) were 1.1% or less and all external validation RMSDs were 3.7% or less. Conclusions: The PRIME T2D Model is a product-independent analysis tool that is available online and offers new approaches to long-standing challenges in diabetes modeling and may become a useful tool for informing healthcare policy. HIGHLIGHTS: The PRIME Type 2 Diabetes (T2D) Model is a new, product-independent simulation model. The model offers new approaches to long-standing challenges in diabetes modeling. PRIME T2D Model projects outcomes consistent with those from clinical trials. The model is designed to be a useful tool for informing healthcare policy in T2D.